Amphastar Pharmaceuticals (AMPH): Rasio rega marang prakiraan pendapatan
The forward P/S ratio reflects the market valuation of future revenues for Amphastar Pharmaceuticals (AMPH), with the latest value recorded as 1.10. Stringent FDA requirements and patent protection for delivery systems create significant barriers to entry. Current growth is supported by sales of nasal glucagon and injectable analogs, while operational efficiency is enhanced by leveraging external partners for clinical trials and packaging.
Rincian metrik lan analitis perusahaan Amphastar Corp (AMPH)
- rega saiki lan proyeksi nilai saham:
- data kapitalisasi bursa:
- indikator nilai buku ekuitas:
- data tingkat utang lan likuiditas finansial:
Total Utang marang Modal Amphastar Pharmaceuticals|AMPH - Utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas Amphastar Pharmaceuticals|AMPH - Gunggung kewajiban utang perusahaan|Utang marang nilai buku Amphastar Corp|AMPH - Gedhene kewajiban jangka dawa|Utang jangka cendhak perusahaan Amphastar Pharmaceuticals|Likuiditas cepet amphastar.com
- data bathi bisnis lan rasio investasi:
AMPH - Bathi pungkasan|Bathi mangsa ngarep Amphastar Pharmaceuticals|AMPH - Nilai perusahaan marang bathi resik|Rega marang bathi mangsa ngarep Amphastar|AMPH - Rasio kapitalisasi marang bathi lan wutah|Pangali EV/EBITDA Amphastar Corp|AMPH - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi resik saben saham (EPS TTM) Amphastar Pharmaceuticals|AMPH - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan amphastar.com|AMPH - Tambahing bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Amphastar Pharmaceuticals
- informasi babagan volume dodolan lan pendapatan:
Analisis komprehensif perusahaan:Amphastar Pharmaceuticals, Inc. (AMPH)
The complexity of producing inhalation generics and stringent FDA oversight create sustainable competitive advantages for Amphastar Pharmaceuticals (AMPH). By analyzing the forward P/S ratio, an investor assesses current market capitalization relative to projected revenue for the coming year. This metric helps smooth out reporting gaps by measuring market expectations regarding business growth rates. Elevated indicator values signal that the asset is overbought and increase the risk of a price correction.
Perusahaan pesaing
Multiplikator Forward P/S HLN (Haleon)|Multiplikator Forward P/S Kenvue Inc KVUE|VRNA - Rasio rega marang prakiraan pendapatan|Jyong Bio (MENS) - Multiplikator forward rega marang pendapatan|Ligand Pharmaceuticals (LGND) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan AMRX (amneal.com)|PRGO (Perrigo) - Multiplikator Forward P/S|ALVO: Rega forward marang dodolan|Multiplikator Forward P/S LQDA|Multiplikator Forward P/S Galapagos Corp (GLPG)|Rasio rega marang prakiraan pendapatan ANI Pharmaceuticals ANIP|Rasio kapitalisasi marang dodolan sing dikarepake mannkindcorp.com (MNKD)|PCRX: Multiplikator forward rega marang pendapatan|ARS Pharmaceuticals Inc - Rasio rega marang pendapatan sing dikarepake|TBPH: Multiplikator Forward P/S|Aquestive Corp (AQST) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan scPharmaceuticals, Inc.|TECX: Rega forward marang dodolan|Multiplikator forward rega marang pendapatan TNXP (Tonix Pharmaceuticals Holding Corp.)|SXTC (sxtchina.com) - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Eupraxia Pharmaceuticals Inc. EPRX|BHST (BioHarvest Sciences Inc) - Rega mangsa ngarep marang pendapatan|eXoZymes Inc - Multiplikator Forward P/S|Rega forward marang dodolan ORMP (Oramed Pharmaceuticals)|ENTX: Multiplikator Forward P/S|MindWalk Holdings, Inc. (HYFT) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan ABVC BioPharma Inc|CPIX: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Quantum BioPharma Ltd (QNTM)|Multiplikator forward rega marang pendapatan fibrogen.com FGEN|Multiplikator Forward P/S TELO (Telomir Pharmaceuticals, Inc.)|Multiplikator Forward P/S Rani Therapeutics Holdings RANI|Synergy CHC Corporation - Multiplikator Forward P/S|Rallybio Corporation (RLYB) - Multiplikator forward rega marang pendapatan|LEXX: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep pulmatrix.com (PULM)|Multiplikator forward rega marang pendapatan PTHL|Multiplikator Forward P/S Aptorum|Multiplikator forward rega marang pendapatan LYRA (Lyra Therapeutics, Inc)|Rasio rega marang pendapatan sing dikarepake IBO|Multiplikator Forward P/S TNFA (TNF Pharmaceuticals, Inc.)|Rasio kapitalisasi marang dodolan sing dikarepake cbdMD Inc. (YCBD)|PainReform - Multiplikator Forward P/S|Altamira Therapeutics (CYTO) - Multiplikator forward rega marang pendapatan|LIPO: Multiplikator Forward P/S|OptiNose Corp (OPTN) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan Pieris Pharmaceuticals|Rasio rega marang prakiraan pendapatan PROC|Rasio rega marang prakiraan pendapatan Petros Pharmaceuticals, Inc. (PTPI)|Rasio kapitalisasi marang dodolan sing dikarepake Qilian International Holding Group|Multiplikator Forward P/S SLRN (ACELYRIN, Inc.)|Multiplikator Forward P/S TFF Pharmaceuticals, Inc TFFP
